Insights on the High Affinity Nerve Growth Factor Receptor Market to 2027 | Industry Statistics, Emerging Demands, Forecast to 2027

The global high affinity nerve growth factor receptor market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Nerve growth factor (NGF) is an insulin-like protein. It regulates the growth, development and maintenance of sympathetic and embryonic sensory neurons. The major factor driving the growth of the market is the increasing prevalence of atopic dermatitis across the globe.

According to the Allergy & Asthma Network, an estimated 18 million people have atopic dermatitis with 9.6 million children diagnosed with the condition in the US. Additionally, an estimated 3.2 million people have moderate to severe atopic dermatitis with more than 30% reported sleep disturbances due to the condition. Furthermore, it is more common in females than males. Moreover, AD poses a burden of $316 million per year globally. Apart from this, NGF mediates its effects in atopic dermatitis by binding to two classes of transmembrane receptors which include a high-affinity receptor and a low-affinity receptor. Hence, the increasing prevalence of atopic dermatitis is driving the demand for high affinity nerve growth factor receptors as it plays an important role in the treatment of pathogenesis of atopic dermatitis-like skin lesions which in turn is driving the growth of the market.

To Request a Sample of our Report on High Affinity Nerve Growth Factor Receptor Market: https://www.omrglobal.com/request-sample/high-affinity-nerve-growth-factor-receptor-market

Some major players in the market include Astellas Pharma Inc., Pfizer Inc., and Merck & Co Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in January 2020, Pfizer and Lilly filed for the approval of Tanezumab from the US FDA. It is a first-in-class NGF inhibitor at the lower 2.5mg dose used for the treatment of osteoarthritis pain.

Market Coverage

· The market number available for - 2020-2027

· Base year- 2020

· Forecast period- 2021-2027

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Astellas Pharma Inc., Pfizer Inc., and Merck & Co Inc., among others.

(Get 15% Discount on Buying this Report)

A full Report of High Affinity Nerve Growth Factor Receptor Market is Available @ https://www.omrglobal.com/industry-reports/high-affinity-nerve-growth-factor-receptor-market

Global High Affinity Nerve Growth Factor Receptor Market Report by Segment

By Type

• ASP-7962

• AZD-7451

• BNN-27

• Cenegermin

• CRB-0089

• Others

By Application

• Atopic Dermatitis

• Cancer

• Others

Global High Affinity Nerve Growth Factor Receptor Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.